Net clinical benefit of direct oral anticoagulants in atrial fibrillation patients with or without diabetes mellitus: a meta-analysis of outcome trials

Direct oral anticoagulants (DOACs) are gradually replacing warfarin in the treatment of non-valvular atrial fibrillation because outcome comparison trials were constantly associated with a reduction of 1) stroke or systemic embolism events, and 2) major bleeding events [1 –4]. Whether the beneficial effect of DOACs vs warfarin on fatal and non-fatal outcomes is consistent to patients with or without diabetes mellitus (DM) has been previously approached by meta-analyses of the available outcome trials [5–7], in which no differential outcome effect was noticed.

Source: Diabetes Research and Clinical Practice - November 15, 2021 Category: Endocrinology Authors: Sotirios Drogkaris, Costas Thomopoulos, Theodoros Kalos, Eleni Manta, Costas Tsioufis Source Type: research